We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Advanced Melanoma

Journal Scan / Research · August 25, 2022

Efficacy of Anti–PD-1 Therapy and/or Ipilimumab in Acral Melanoma

Journal for immunotherapy of cancer

 

Additional Info

Disclosure statements are available on the authors' profiles:

Journal for immunotherapy of cancer
Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma
J Immunother Cancer 2022 Jul 01;10(7)e004668, P Bhave, T Ahmed, SN Lo, A Shoushtari, A Zaremba, JM Versluis, J Mangana, M Weichenthal, L Si, T Lesimple, C Robert, C Trojanello, A Wicky, R Heywood, L Tran, K Batty, F Dimitriou, A Stansfeld, C Allayous, JK Schwarze, MJ Mooradian, O Klein, I Mehmi, R Roberts-Thomson, A Maurichi, HL Yeoh, A Khattak, L Zimmer, CU Blank, E Ramelyte, KC Kähler, S Roy, PA Ascierto, O Michielin, PC Lorigan, DB Johnson, R Plummer, C Lebbe, B Neyns, R Sullivan, O Hamid, M Santinami, GA McArthur, AM Haydon, GV Long, AM Menzies, MS Carlino

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading